Dinical value of blood biomarker ST2 in patients with chronic heart failure
- Authors: Alieva A.M.1, Pinchuk T.V.1, Almazova I.I.2, Ettinger O.A.1, Valiev R.K.3, Batov M.A.1, Nikitin I.G.1
-
Affiliations:
- Pirogov Russian National Research Medical University
- National Research Center for Therapy and Preventive Medicine
- Loginov Moscow Clinical Scientific and Practical Center
- Issue: Vol 23, No 6 (2021)
- Pages: 522-526
- Section: Articles
- URL: https://journals.rcsi.science/2075-1753/article/view/95508
- DOI: https://doi.org/10.26442/20751753.2021.6.200606
- ID: 95508
Cite item
Full Text
Abstract
Full Text
##article.viewOnOriginalSite##About the authors
Amina M. Alieva
Pirogov Russian National Research Medical University
Email: amisha_alieva@mail.ru
канд. мед. наук, доц. каф. Moscow, Russia
Tatiana V. Pinchuk
Pirogov Russian National Research Medical University
Email: doktor2000@inbox.ru
канд. мед. наук, доц. Moscow, Russia
Ilda I. Almazova
National Research Center for Therapy and Preventive Medicineврач-преподаватель Moscow, Russia
Olga A. Ettinger
Pirogov Russian National Research Medical Universityканд. мед. наук, доц. каф. Moscow, Russia
Ramiz K. Valiev
Loginov Moscow Clinical Scientific and Practical Centerканд. мед. наук, зав. Moscow, Russia
Maxim A. Batov
Pirogov Russian National Research Medical Universityстудент Moscow, Russia
Igor G. Nikitin
Pirogov Russian National Research Medical Universityд-р мед. наук, проф., зав. каф. Moscow, Russia
References
- Pascual-Figal DA, Lax A, Perez-Martinez MT, et al. Clinical relevance of sST2 in cardiac diseases. Clin Chem Lab Med. 2016;54(1):29-35. doi: 10.1515/cclm-2015-0074
- Januzzi JL Jr, Ahmad T, Mulder H, et al. Natriuretic Peptide Response and Outcomes in Chronic Heart Failure With Reduced Ejection Fraction. J Am Coll Cardiol. 2019;74(9):1205-17. doi: 10.1016/j.jacc.2019.06.055
- Ciccone MM, Cortese F, Gesualdo M, et al. A Novel Cardiac Bio-Marker: ST2: A Review. Molecules. 2013;18(12):15314-28. doi: 10.3390/molecules181215314
- Sanada S, Hakuno D, Higgins LJ, et al. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Invest. 2007;117:1538-49. doi: 10.1172/JCI30634
- Januzzi JL Jr. ST2 as a Cardiovascular Risk Biomarker: From the Bench to the Bedside. J Cardiovasc Transl Res. 2013;6(4):493-500. doi: 10.1007/s12265-013-9459-y
- Nadar SK, Shaikh MM. Biomarkers in Routine Heart Failure Clinical Care. Card Fail Rev. 2019;5(1):50-6. doi: 10.15420/cfr.2018.27.2
- Mueller T, Jaffe AS. Soluble ST2: Analytical considerations. Am J Cardiol. 2015;115(7 Suppl):8B-21B. doi: 10.1016/j.amjcard.2015.01.035
- Boisot S, Beede J, Isakson S, et al. Serial sampling of ST2 predicts 90-day mortality following destabilized heart failure. J Card Fail. 2008;14(9):732-8. doi: 10.1016/j.cardfail.2008.06.415
- Mueller T, Dieplinger B, Gegenhuber A, et al. Increased plasma concentrations of soluble ST2 are predictive for 1-year mortality in patients with acute destabilized heart failure. Clin Chem. 2008;54(4):752-6. doi: 10.1373/clinchem.2007.096560
- Копьева К.В., Гракова Е.В., Тепляков А.Т. Новые маркеры сердечной недостаточности: значение для диагностики и прогнозирования NT-proBNP и интерлейкиновых рецепторов - членов семейства ST2. Комплексные проблемы сердечно-сосудистых заболеваний. 2018;7(1):94-101
- Lupon J, de Antonio M, Vila J, et al. Development of a novel heart failure risk tool: The Barcelona Bio-Heart Failure Risk Calculator (BCN bio-HF Calculator). PLoS One. 2014;9(1):e85466. doi: 10.1371/journal.pone.0085466
- Emdin M, Aimo A, Vergaro G, et al. sST2 predicts outcome in chronic heart failure beyond NT-proBNP and high-sensitivity troponin T. J Am Coll Cardiol. 2018;72(19):2309-20. doi: 10.1016/j.jacc.2018.08.2165
- Gaggin HK, Motiwala S, Bhardwaj A, et al. Soluble concentrations of the interleukin receptor family member ST2 and 0-blocker therapy in chronic heart failure. Circ Heart Fail. 2013;6(6):1206-13. DOI:10.1161/ CIRCHEARTFAILURE.113.000457
- Dudek M, Kaluzna-Oleksy M, Migaj J, Straburzynska-Migaj E. Clinical value of soluble ST2 in cardiology. Adv Clin Exp Med. 2020;29(10):1205-10. doi: 10.17219/acem/126049
- Coronado MJ, Bruno KA, Blauwet LA, et al. Elevated sera sST2 is associated with heart failure in men №50 years old with myocarditis. J Am Heart Assoc. 2019;8(2):e008968. doi: 10.1161/JAHA.118.008968
- Farcaf AD, Anton FP, Goidescu CM, et al. Serum soluble ST2 and diastolic dysfunction in hypertensive patients. Dis Markers. 2017;2714095. doi: 10.1155/2017/2714095
- Chen C, Qu X, Gao Z, et al. Soluble ST2 in patients with nonvalvular atrial fibrillation and prediction of heart failure. Int Heart J. 2018;59(1):58-63. doi: 10.1536/ihj.16-520
- Okar S, Kaypakli O, §ahin DY, Ko<; M. Fibrosis marker soluble ST2 predicts atrial fibrillation recurrence after cryoballoon catheter ablation of nonvalvular paroxysmal atrial fibrillation. Korean Circ J. 2018;48(10):920-9. doi: 10.4070/kcj.2018.0047
- Ibrahim NE, Lyass A, Gaggin HK, et al. Predicting new-onset HF in patients undergoing coronary or peripheral angiography: Results from the Catheter Sampled Blood Archive in Cardiovascular Diseases (CASABLANCA) study. ESC Heart Fail. 2018;5(3):240-8. doi: 10.1002/ehf2.12268
- Patel DM, Thiessen-Philbrook H, Brown JR, et al. Association of plasma soluble ST2 and galectin 3 with cardiovascular events and mortality following cardiac surgery. Am HeartJ. 2020;220:253-63. doi: 10.1016/j.ahj.2019.11.014
- Lupon J, de Antonio M, Galan A, et al. Combined use of the novel biomarkers high sensitivity troponin T and ST2 for heart failure risk stratification vs conventional assessment. Mayo Clin Proc. 2013;88(3):234-43. doi: 10.1016/j.mayocp.2012.09.016:234-43
- Anand IS, Rector TS, Kuskowski M, et al. Prognostic Value of Soluble ST2 in the Valsartan Heart Failure Trial. Circ Heart Fail. 2014;7(3):418-26. doi: 10.1161/CIRCHEARTFAILURE.113.001036
- Vorovich E, French B, Ky B, et al. Biomarker predictors of cardiac hospitalization in chronic heart failure: a recurrent event analysis. J Card Fail. 2014;20(8):569-76. doi: 10.1016/j.cardfail.2014.05.013
- Ahmad T, Fiuzat M, Neely B, et al. Biomarkers of myocardial stress and fibrosis as predictors of mode of death in patients with chronic heart failure. JACC Heart Fail. 2014;2:260-8. doi: 10.1016/j.jchf.2013.12.004
- Yancy CW, Jessup M, Bozkurt B, et al. American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;62(16):e147-239. doi: 10.1016/j.jacc.2013.05.019
- Gaggin HK, Szymonifka J, Bhardwaj A, et al. Head-to-head comparison of serial soluble ST2, growth differentiation factor-15, and highly-sensitive troponin T measurements in patients with chronicheart failure. JACC Heart Fail. 2014;2(1):65-72. doi: 10.1016/j.jchf.2013.10.005
- Caselli C, D’Amico A, Ragusa R, et al. IL-33/ST2 pathway and classical cytokines in end-stage heart failure patients submitted to left ventricular assist device support: a paradoxic role for inflammatory mediators? MediatorsInflamm. 2013;2013:498703. doi: 10.1155/2013/498703
- Zilinski JL, Shah RV, Gaggin HK, et al. Measurement of multiple biomarkers in advanced stage heart failure patients treated with pulmonary artery catheter guided therapy. Crit Care. 2012;16(4):R135. doi: 10.1186/cc11440
- Dieplinger B, Mueller T. Soluble ST2 in heart failure. Clin Chim Acta. 2015;443:57-70. doi: 10.1016/j.cca.2014.09.021